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Oxidative Stress and Iron Overload 
in β-Thalassemia: An Overview
Nadia Maria Sposi
Abstract
In β-thalassemia, the erythropoietic process is markedly altered, and the lack 
or reduced synthesis of β-globin chains induces an excess of free α-globin chains 
within the erythroid cells. Aggregation, denaturation, and degradation of these 
chains lead to the formation of insoluble precipitates causing damage to the red 
blood cell membrane. One of the major consequences in this genetic disorder is 
iron overload due to ineffective erythropoiesis and premature hemolysis in the 
plasma and in major organs such as heart, liver, and endocrine glands. The chapter 
describes the etiology of iron accumulation, the role of hepcidin in regulating 
increased iron absorption, and the pathophysiology resulting from excess of “free 
iron” and discusses new ways to decrease the iron overload and to neutralize its 
deleterious effects in the tissues other than iron chelation.
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1. Introduction
β-thalassemias are a group of hereditary blood disorders characterized by the 
reduced or absent synthesis of β-globin chains representing one of the most com-
mon autosomal recessive disorders worldwide. It is prevalent in the Mediterranean 
countries, the Middle East, and Southeast Asia, as well as countries along the 
Americas, coincidental with the occurrence of malaria. Carriers of β-thalassemia 
genes are considered relatively protected against malaria parasite. At present, 
because of vast population migration and intermarriage between different ethnic 
groups, β-thalassemia is also common in North and South America, Northern 
Europa, Australia, and the Caribbean. As a consequence of the reduced or absent 
synthesis of β-globin chains, there is an excess on α-globin chains that are instable 
and precipitate in red blood cell precursors causing abnormal cell maturation 
and their premature destruction in the bone marrow (ineffective erythropoiesis). 
Red blood cells that survive to reach the peripheral circulation are prematurely 
destroyed in the spleen. The break down products of Hb, heme, and iron catalyze 
chemical reactions that generate free radicals, including reactive oxygen spe-
cies (ROS), which in excess are toxic, causing damage to vital organs such as 
the heart and liver and the endocrine system [1]. More than 300 different point 
mutations cause β-thalassemia. They are inherited in a multitude of genetic 
combinations responsible for clinical manifestations extremely diverse, spanning 
a broad spectrum from the transfusion-dependent state of thalassemia major 
(TM) to the asymptomatic state of heterozygous carriers for β0 or β+ (thalas-
semia trait). β-thalassemia intermedia requires only periodic blood transfusion, 
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while β-thalassemia minor does not require a specific treatment. One of the 
major consequences in this genetic disorder is iron overload due to multiple blood 
transfusions, ineffective erythropoiesis, and premature hemolysis in the plasma. 
Cardiomyopathy is the most common cause of death in transfusion-dependent 
thalassemia patients as a consequence of iron overloading. Thanks to the signifi-
cant improvement in therapy, patients with β-thalassemia may reach an advanced 
age. This is associated with clinical symptoms that are the consequence of the 
disease itself and the treatment modalities. The aim of this chapter is that to give a 
complete picture of current knowledge on the etiology of iron accumulation, the 
role of hepcidin in regulating increased iron absorption, and the pathophysiology 
resulting from excess of “free iron.” It will also be explored whether there are ways 
to decrease the iron overload and to neutralize its deleterious effects in the tissues 
other than iron chelation (for an extensive revision, see Refs. [1–5]).
2. Iron overload in β-thalassemia
In β-thalassemia, as well as in other acquired and hereditary hemolytic anemia, 
iron overload is a common and serious complication and represents a major cause 
of morbidity and premature mortality in these patients. Hemoglobin instability, 
frequent blood transfusion, and increased iron absorption from the gastrointestinal 
tract represent the main causes of iron overload in β-thalassemia. Iron deposition 
occurs in visceral organs (mainly in the heart, liver, and endocrine glands), caus-
ing tissue damage and ultimately organ dysfunction and failure. Iron homeostasis 
depends on a coordinated regulation of molecules involved in the import of this 
element and those exporting it out of the cells. In particular, the iron status reflects 
the balance among iron uptake from the diet, its storage and mobilization, and its 
utilization [1]. Normally, 1–2 mg of iron is absorbed from the diet per day, with 
an equivalent amount lost by the turnover of gastrointestinal tract epithelial cells. 
In β-thalassemia and other transfusion-dependent anemias, iron overload may 
accumulate in relatively short time because there are no physiologically regulated 
means of iron excretion. Iron is essential for several vital biological processes. It 
regulates enzymatic activity and oxidation-reduction reactions playing a pivotal 
role in proliferation and cell survival. Iron ensures the transport of oxygen and the 
catalysis of reactions involved in electron transfer, DNA synthesis, and nitrogen 
fixation. However, it is also highly toxic due to its ability to react with oxygen and 
catalyze the production of reactive oxygen species (ROS). In solution, iron can exit 
in two states of oxidation, Fe (II) and Fe (III), and is very poorly soluble at physi-
ological pH, especially when it is in the oxidized form Fe (III). Living organisms 
have thus developed many proteins to carry iron in biological fluids and transport 
it through cellular membranes and to store it in a non-toxic and easily mobilizable 
form [2, 6–8]. Iron is bound to transferrin in the plasma, but the iron overload 
in β-thalassemia patients saturates the ability of the transferrin iron transport 
system, leading to nontransferrin bound iron (NTBI) and labile plasma iron (LPI) 
starting to circulate in plasma and subsequently becoming deposited inside the 
susceptible cells [9, 10]. Rather than using the transferrin receptor, NTBI enters 
cells by nontransferrin pathways [1, 11]. Long-term uptake and accumulation of 
NTBI and LIP, its redox active component, lead to increate levels of storage iron and 
labile cellular iron [12]. Tissues susceptible to iron accumulation by this mechanism 
include the liver, endocrine system, and myocardium [13]. When the magnitude of 
the cellular LIP exceeds the capacity of the cell to synthesize new ferritin molecule, 
a critical concentration is reached that can generate reactive oxygen species (ROS). 
ROS produced by the metabolism of NTBI play a central role in inducing cellular 
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dysfunction, apoptosis, and necrosis [14]. A variety of ROS, most notably hydroxyl 
radicals, increase lipid peroxidation and organelle damage, leading to cell death 
and fibrogenesis mediated by transforming growth factor β-1 (TGF-beta-1) [15]. 
An underappreciated effect of iron overload is increased the infection risk that is a 
high cause of mortality in β-thalassemia patients [16]. The LIP has been suggested 
as a low-molecular-weight intermediate or transitory pool between extracellular 
iron and intracellular firmly bound iron [17]. The intracellular LIP is redox active, 
catalyzing the Fenton and Haber-Weiss reactions that generate ROS [18]. Excess 
ROS are cytotoxic through their interaction with cellular components, such as DNA, 
proteins, and lipids, causing damage to vital organs [19].
3. Strategies to remove iron in excess
β-thalassemia is a significant health problem in various areas of the world due 
to its frequency and severity. The standard treatment of β-thalassemia is currently 
based on transfusion therapy, iron chelation, and, in rare cases, splenectomy. This 
has led to an increased survival and amelioration of the quality of life, although 
many patients continue to be affected by cardiac disease and other clinical com-
plications, e.g., developed endocrine failure and delayed pubertal maturation. The 
only approach that may lead to a definitive cure for β-thalassemia is represented by 
allogenic hemopoietic stem cell transplantation, but the need to control transplant-
related complications and the requirement for matched donors make this option 
not available to most patients. Thus, the main therapeutic option for the majority of 
patients remains to be supportive care in the form of blood transfusion combined 
with chelation therapy [2]. The function of iron chelators is that to remove excess 
iron from the plasma and the cells by binding the labile and chelatable iron, thus 
facilitating its excretion through the urine and feces. Deferoxamine was the first 
iron chelator to be used clinically and is given by a slow, continuous, subcutaneous, 
overnight infusion through a portable pump. Its side effects are minimal, but its 
mode of administration results in low compliance [1]. Deferasirox presents several 
side effects [1, 2]. Neutropenia is the main potential complication of deferiprone, 
the first effective oral iron chelator in removing excess iron from the organs and 
from the heart. The use of a combination of chelators leads to an improvement 
in the efficacy of chelation therapy: deferiprone may mobilize iron from tissues into 
the circulation, while deferoxamine binds and facilitates its excretion in the urine 
(the “shuttle mechanism”) [1]. An additional potential approach to reduce iron 
overload is the downregulation of transferrin receptor 1 (TfR1) by administration of 
exogenous iron-free (apo) transferrin. In addition to free iron, some iron-containing 
compounds, due to hemolysis, are elevated in the plasma of β-thalassemia patients. 
They are free hemin and hemoglobin and are of considerable toxicity [1, 2]. These 
compounds are neutralized by their scavengers: hemopexin for free hemin and 
haptoglobin for free hemoglobin. These proteins are reduced in β-thalassemia 
patients, leaving free, un-neutralized hemin, and hemoglobin. The administration 
of hemopexin and haptoglobin may be suggested to reduce iron toxicity.
4. Strategies to modulate iron absorption
The discovery of hepcidin has led to an important advancement in the under-
standing of iron metabolism. Hepcidin is a key regulator of whole body iron homeo-
stasis originally identified from urine as an antimicrobial peptide produced in the 
hepatocytes [20]. Mutations in the human HAMP gene or targeted deletion of the 
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HAMP gene in mice result in massive iron overload [21]. Conversely, high levels of 
hepcidin lead to decreased iron absorption and iron-restricted anemias indicating 
that hepcidin is a negative regulator of iron transport into plasma. Many experi-
mental data suggested that the hepcidin could be the regulator of iron absorption 
and recycling acting principally or solely by binding to ferroportin, the only known 
cellular iron exporter. The systemic iron homeostasis is controlled by hepcidin-
ferroportin interaction: hepcidin binds to ferroportin and induces its internaliza-
tion and degradation, thus regulating the distribution of iron in the body. When 
hepcidin concentration increases, hepcidin binds to ferroportin, causing its phos-
phorylation, internalization, ubiquitylation, sorting through the multivesicular 
body pathway, and degradation in lysosomes, and iron is retained within the cells 
in cytoplasmic ferritin [22–25]. The expression of hepcidin is regulated by different 
stimuli at the transcriptional level: hypoxia, iron deficiency, erythroid expansion, 
and anemia are all negative regulators of hepcidin expression, while transferrin 
receptor 2 (TfR2), the membrane isoform of hemojuvelin (HJV), IL-6, iron, and the 
hemochromatosis protein HFE are all positive regulators of hepcidin transcription 
[2]. In β-thalassemia, in spite of iron overload, hepcidin production is generally 
low, and consequently, iron absorption is high. The process of differentiation and 
maturation of erythroid precursors is markedly altered in β-thalassemia (ineffec-
tive erythropoiesis). An excess of free α-globin chains within the red blood cells is 
the consequence of the reduced or lack synthesis of β-globin chains. Aggregation, 
denaturation, and degradation of these chains lead to the formation of insoluble 
precipitates that cause oxidative membrane damage within the red blood cell and 
developing erythroblasts (Figure 1A) [26]. Ineffective erythropoiesis is accompa-
nied by a massive iron overload, due to an increase in iron absorption by the gas-
trointestinal tract and to frequent blood transfusions. Nevertheless, iron overload 
occurs also in patients who have not received transfusions such as patients suffering 
from thalassemia intermedia [27, 28]. If iron was a dominant regulator, patients 
with β-thalassemia should express very high levels of hepcidin in serum in order 
to decrease intestinal iron absorption. By contrast, the levels of hepcidin are very 
low in these patients, suggesting that the ineffective erythropoiesis alone is able to 
suppress the synthesis of hepcidin in spite of the presence of a severe iron overload  
[25, 29–31]. Transfusions of erythrocyte partially rerelieved suppression of 
hepcidin, but transfusions add large amounts of exogenous iron and lead to 
iron overload. Hepcidin mRNA expression in the HepG2 cell line by serum from 
β-thalassemia patients suggested the existence of a negative erythropoietic 
regulator of hepcidin expression [32]. The nature of this humoral factor is still 
uncharacterized but may include growth differentiation factor (GDF-15), twisted 
gastrulation protein homolog 1 (TWSG1), soluble transferrin receptor, and eryth-
roferrone, which are all overproduced by the proliferating erythroid precursors 
(Figure 2). Controlling absorption of iron may be beneficial to the administration 
of synthetic hepcidin or of agents that increase its expression. Hepcidin agonists or 
stimulators of hepcidin production are being developed for the treatment or pre-
vention of iron overload in hepcidin deficiency states, including hereditary hemo-
chromatosis and β-thalassemia [33]. The rationale for the use of hepcidin agonists 
is justified by two principal observations: first, the phlebotomy is an expensive and 
effective treatment for iron overload that is acceptable to must but not all patients 
affected by hereditary hemochromatosis; second, iron-loading anemias cannot be 
treated in this way and require iron chelation therapy, which is not well tolerate 
by many patients. Hepcidin agonists are agents that replace hepcidin activity or 
stimulate its endogenous production and, in both hereditary hemochromatosis and 
iron loading anemia, could prevent iron accumulation by redistributing iron from 
parenchymal tissues to macrophages where iron is less toxic [34, 35].
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TMPRSS6 suppression could be an alternative approach to increase hepatic 
synthesis of hepcidin. It is a transmembrane serine protease (matriptase-2) that 
normally suppresses the synthesis of hepcidin by deactivating hemojuvelin (HJV) 
[36]. Data showed that the deletion of TMPRSS6 gene in mouse model increased 
hepcidin expression resulting in anemia improvement, ineffective erythropoiesis, 
and splenomegaly reducing and decreased iron loading [37]. An improvement 
in anemia and iron overload has been showed in mice and in preclinical studies 
using antisense oligonucleotides or small interfering RNAs (siRNA9 decreasing 
TMPRSS6) [38, 39]. The somministration of exogenous transferrin, through the 
downregulation of TfR1, increased erythroid precursor enucleation and improved 
terminal erythroid differentiation and maturation in β-thalassemic mice [40, 41]. 
Recently, a new iron metabolism regulating factor produced in erythroblasts in 
response to erythropoietin, ERFE (erythroferrone), was identified. In murine mod-
els with β-thalassemia intermedia, ERFE is highly expressed and mediates hepcidin 
suppression and contributes to iron overload. On the contrary, a deficiency of ERFE 
leads to an increase in hepcidin expression, a significant reduction in iron overload, 
and a slight improvement of erythropoietic indices [42]. All these data indicate that 
the inhibition of ERFE may be a future target with therapeutic potential in diseases 
Figure 1. 
(A) Erythroid expansion and ineffective erythropoiesis represent oxidative events in the bone marrow.  
(B). Oxidative events in the circulation: (1) hemolysis leads to hemoglobin release in the plasma. Autoxidation 
of free hemoglobin produces ROS, free heme, and iron; (2) eryptosis and senescence: two different mechanisms 
of endocytosis of red blood cells (RBCs) by macrophages; and (3) membrane oxidative damage by ROS, 
free heme, and iron: activation of NF-κB and AP-1 by ROS and heme increases the production of pro-
inflammatory cytokines (IL-1, IL-6, and TNFα) and adhesion molecules on the endothelium. Activated 
leucocytes generate more ROS by their NAPDH oxidase, creating a loop of oxidative stress and inflammation.
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with ineffective erythropoiesis and iron overload as β-thalassemia. Agents targeting 
hepcidin expression are more likely to be beneficial to patients with NTDT than 
those with TDT because transfusional iron overload is not mediated by low hepcidin 
levels. However, mini-hepcidins and TMRSS6 inhibitors can be evaluated for use in 
patients with TDT because improvement in erythropoiesis could potentially reduce 
transfusion requirements [43].  All discussed novel agents merit further evaluation 
of efficacy and safety in both preclinical and clinical development studies.
5. Oxidative stress in β-thalassemia
Oxidative stress plays a major role in pathophysiology of β-thalassemia, although 
it is not the primary etiology of disease. The cell oxidative status depends on the 
equilibrium between oxidants and anti-oxidants. The reactive oxygen species (ROS) 
are oxidants produced mainly as byproducts of cellular respiration, while reduced 
glutathione is an example of anti-oxidants. A balance between oxidants and anti-
oxidants is crucial for normal physiology. ROS are utilized from the cells as regula-
tors in many physiological processes, including proliferation and differentiation of 
the erythroid precursors. Oxidative stress ensues in many pathological processes 
when the balance between oxidants and anti-oxidants is broken, as it occurs in 
β-thalassemia. Excess ROS cause cytotoxicity by binding to cell components such as 
DNA, proteins, and membrane lipids [19]. In β-thalassemia, the main consequence 
of the unstable Hbs and iron overload is the oxidative stress. It mediates many of 
symptoms due to oxidative damage to red blood cells, leukocytes (recurrent infec-
tions), platelets (hypercoagulable state), as well as in heart, liver, and the endocrine 
glands (Figures 1A and B) [19, 44–46]. Endogenous and exogenous antioxidants 
may ameliorate the oxidative stress in β-thalassemia. They act scavenging and 
inactivating ROS and correcting their damage to cellular components. We introduce 
Figure 2. 
Dysregulation of iron homeostasis in β-thalassemia disease. Ineffective erythropoiesis and premature death of 
red blood cells are the main cause of anemia in β-thalassemia patients. Erythropoietin production induced by 
anemia causes an increase in erythropoiesis activating secretion of erythroid factors such as GDF15, TWSG1, 
and ERFE. The suppression of hepcidin expression caused by an excess of eryhtroid factors leads to an increase 
in intestinal iron absorption, release of iron from the liver, and reticuloendothelial system. All these lead to iron 
overload. GDF15: Growth differentiation factor 15; TWSG1: Twisted-gastrulation 1; ERFE: Erythroferrone.
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many antioxidants by nutrition. For example, a moderate wine consumption and 
a “Mediterranean diet” are thought to have a protective effect due to their high 
contents of antioxidants [47, 48]. Antioxidants can also be taken as food additives, 
or as crude extracts, such as preparation of papaya fermented and curcumin, either 
as pure compounds such as vitamins C and E and Q10 [49]. An improvement in 
many parameters of oxidative stress by using such additives in β-thalassemia was 
observed, but a clear clinical benefit, such as reducing transfusion dependence, was 
less successful. A combination of drugs affecting both the oxidative stress and the 
iron overload can give an effective outcome. Forkhead-box-O3 (Foxo3) is a critical 
transcription factor that protects the cell from oxidative stress by upregulating anti-
oxidant enzymes during early stages of erythropoiesis [50]. At early stages, Foxo3 is 
phosphorylated by proteins of the EPOR-P13K/AKT/mTOR signaling pathway and 
is translocated out of the nucleus, where it remains inactivated. At late stages, Foxo3 
is relocated into the nucleus, gets activated, and induces the production of antioxi-
dants that neutralize ROS to allow efficient erythropoiesis [1, 36, 51, 52]. In mice 
with β-thalassemia intermedia, downregulation of Foxo3, as a result of persistent 
activation of EPOR-p13K/AKT/mTOR pathway, was observed. Inactivation of Foxo3 
leads to oxidative damage in late erythroblasts and plays a significant role in the 
process of ineffective erythropoiesis [53]. β-thalassemia patients could be beneficial 
in improving anemia by activation of Foxo3 as a potential inducer of HbF. However, 
the function of Foxo3 in hemoglobinopathies has yet to be elucidated. A remark-
able improvement in erythroid cell maturation, production of β-globin chains, and 
anemia has been observed following the use of rapamycin, an mTOR inhibition, 
in mice with β-thalassemia intermedia [53]. In another study, rapamycin increased 
α-globin expression and HbF production in cultured erythroid precursors from 
patients with β-thalassemia intermedia [54, 55]. Similar findings were reported 
with the use of another Foxo3 activating agent, resveratrol (3,5,4′-trihydroxy-trans-
stilbene), a non-flavonoid polyphenol that upregulates antioxidant enzymes in mice 
with β-thalassemia intermedia [56]. Metformin, an approved drug for diabetes type 
2 and a Foxo3 inducer, has been investigated as an HbF inducer in an ongoing phase 
1 clinical trial in patients with sickle cell anemia and nontransfusion-dependent 
thalassemia (NTDT; NCT02981329) [57]. All these agents are in preclinical studies 
and need further evaluation. Then, further laboratory and clinical investigations 
are required in this field. A factor required for the initiation of translation through 
the binding of tRNA to the ribosomes is the eukaryotic initiation factor 2 (eIF2). It 
is regulated by a mechanism involving phosphorylation at its α-subunit by heme-
regulated eIF2a kinase (HRI) in the erythroid precursors. Stress, as heme deficiency 
and oxidative stress during the late stage of erythroid differentiation, activates 
HRI that coordinates the synthesis of heme and globin. It was demonstrated that 
the phosphorylated α-subunit of eIF2 turned on the activating transcription factor 
4 (ATF4) to diminish oxidative stress in erythroid precursors [58–60]. A selective 
inhibitor of eIF2aP dephosphorylation as salubrinal augmented the HRI signaling 
pathway and reduced the production of hemichromes in β-thalassemia erythroid 
precursors [59]. In another study, salubrinal increased HbF production with a 
concomitant decrease of HbA in differentiating human CD34 cells by a post-
transcriptional mechanism [61]. Thus, manipulation of the HRI-eIF2aP signaling 
pathway could represent a new approach for the treatment of β-thalassemia.
An antioxidant protein that scavenges and inactivates ROS is the peroxire-
doxin-2 (Prx2), essential during erythropoiesis. The expression of this protein is 
upregulated both murine and human β-thalassemia indicating that the oxidative 
stress induces peroxiredoxin-2 as a novel cytoprotective response in β-thalassemic 
erythropoiesis [62, 63]. Heme oxygenase (HO-1) is an enzyme that catalyzes the 
degradation of heme in response to stress, such as oxidative stress or hypoxia, both 
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of which occur in β-thalassemia. In EPO-dependent fetal liver erythropoietic cells 
from β-thalassemic mice, the expression of HO-1 was augmented. The administra-
tion of tin protoporphyrin IX, an HO-1 inhibitor, improved ineffective erythropoi-
esis and Hb levels and decreased spleen size and liver iron [64, 65].
6. Potential role of antioxidants in β-thalassemia
Various antioxidant enzyme systems are activated by the oxidative stress to 
protect the body tissues from its damaging effects in β-thalassemia patients. These 
antioxidants include superoxide dismutase (SOD), catalase, glutathione (GSH), 
thioredoxin (Trx), and ferritin. Superoxide (O2
−) is the first reactive radical pro-
duced, and this radical can be neutralized by SOD. There are three distinct SODs: 
SOD1 (cu/Zn-SOD) is present in cytoplasm, whereas SOD2 (Mn-SOD) is present 
in the mitochondria, and SOD3 is almost exclusively extracellular [66, 67]. Each of 
these distinct SODs performs a specific function in human cells. In β-thalassemia, 
major patients higher levels of erythrocyte superoxide dismutase and glutathione 
peroxidase (GPx) as well as higher plasma malondialdehyde (MDA) were observed 
as compared to healthy controls [68]. Iron overload through repeated blood transfu-
sions and subsequent oxidative stress produced by reactive oxygen species may be 
the cause of increased levels of MDA. The rise in SOD and glutathione peroxidase 
may occur as a result of compensatory mechanisms in response to oxidative stress 
[44]. Neutralization of O2
− produces H2O2, which can be metabolized into nontoxic 
products by a catalase and glutathione peroxidase (GPx) in conjunction with 
glutathione. Location of GPx depends on the subtype, whereas catalase is present in 
peroxisomes [67]. The stability of the cellular and subcellular membranes depends 
mainly on glutathione peroxidase, and the protective antioxidant effect of glutathi-
one peroxidase depends on the presence of selenium. In patients with β-thalassemia, 
major was confirmed the peroxidative status generated by iron overload and the 
high increase in serum ferritin, iron, plasmatic thiobarbituric acid reactive sub-
stances (TBARS), SOD, and glutathione peroxidase activity, while the vitamin E 
and zinc concentration decreased in these patients [44, 69]. Glutathione (GSH) is 
present in nearly all cells in the body and is present in high levels in organs with high 
oxygen consumption and energy production, e.g., the brain [67, 70]. Glutathione, 
in conjunction with its oxidized form (GSSG), plays a major role in controlling 
cellular redox state. The ubiquitous thioredoxin system also plays an important role 
in maintaining the cell’s redox state [67, 71]. Finally, ferritin is considered an endog-
enous antioxidant as it performs the important function of sequestering potentially 
toxic labile iron. When endogenous antioxidants are unable to neutralize oxidative 
stress, as in β-thalassemia, exogenous antioxidants can be used to augment the 
antioxidant system of the body. Iron metabolism underlies the dynamic interplay 
between oxidative stress and antioxidants in many pathophysiological processes. 
Iron overload can affect redox state, and not only this condition can be restored to 
physiological conditions using iron chelation, but also the addition of antioxidants 
to these treatment regimens can be a viable therapeutic approach for attenuating 
tissue damage induced by oxidative stress (Table 1), (Figures 3, [72–74]). Vitamin 
A (β-carotene), vitamin C, vitamin E (α-tocopherol), polyphenols, and other bioac-
tive plant-derived compounds are effective exogenous antioxidants that also regu-
late iron metabolism. At the transcriptional level, antioxidant enzymes are regulated 
by the transcription factor Nrf2, which binds to the antioxidant response element 
(ARE) in the target gene’s promoter region. Nrf2 is believed to be phosphorylated 
by protein kinase C (PKC), which causes the transcription factor to translocate to 
the nucleus, where it activates ARE-containing genes [67, 75], ultimately leading 
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to the neutralization of free radicals and the attenuation of oxidative damage [76]. 
Table 1 summarizes the flavonoids and other antioxidants that regulate both iron 
homeostasis and redox state, in some cases via independent mechanisms. Flavonoids 
are present in a wide variety of plants and represent the most common class of 
polyphenols, organic chemicals that protect the plant from ultraviolet radiation, 
pathogens, and effects of oxidative stress, making them suitable for therapeutic pur-
poses [77, 78]. Examples of flavonoids include quercetin, cathechins, curcumin, and 
kaempferol, which are abundant in fruits, vegetables, legumes, red wine, and green 
tea. Curcumin is a potent flavonoid antioxidant that can chelate iron in addition to 
modulating redox state [79]. A flavonoid-rich extract of orange and bergamot juice 
has been shown to chelate iron in iron-overload A549 cells and to activate the anti-
oxidant enzyme catalase, leading to a decrease in ROS production and membrane 
lipid peroxidation [80]. It is a promising candidate for regulating both oxidative 
stress and iron homeostasis. Quercetin can reduce hepatic iron deposition in mice 
Antioxidant Mechanisms of iron regulation Sources of 
antioxidants
Curcumin • Potent flavonoid antioxidant
• Iron chelator
• Redox state modulator
• Decreased iron levels
• Attenuated lipopolysaccharide (LPS)-induced 
oxidative stress-related inflammation
• Activated hepatic IRPs and TfR1, repressed hepatic 
hepcidin and ferritin synthesis
Curcumin is a bright 
yellow chemical 
produced by Curcuma 
longa plants
Quercetin • Decreased hepatic iron levels
• Reduced iron-related damage
• Increased BMP6, intranuclear SMAD4, SMAD4 
binding to the HAMP promoter, and hepcidin 
expression
Vegetables, leaves, 
grains, red onions, 
kale, red wine, and tea
Flavonoid-rich 
extract of orange 
and bergamot juice
• Decreased ROS production and membrane lipid 
peroxidation by iron chelation in iron-overload 
A549 cells and activation of antioxidant catalase 
enzyme
Citrus fruits
Genistein • Reduced inflammation induced by ethanol and 
oxidative stress in mice
• Increased HAMP promoter activity in both 
zebrafish and human hepatocytes via Stat3- and 
Smad4-dependent process
Lupin, fava beans, soy 
beans, kudzu, psoralea, 
Maackia amurensis, 
and Flemingia vestita
Silymarine • Iron-chelating properties Silybum marianum 
extract
Ferulic acid • Decreased iron-induced oxidative stress, reduced 
liver injury, and ROS production
• Increased hepatic antioxidant and mitochondrial 
membrane potential
Vegetables, popcorn, 
bamboo shoots, cereals 
(bran, wheat, and 
barley grain)
Resveratrol • Reduced myocardial damage by modulating vas-
cular cell function, low density lipoprotein (LDL) 
oxidation, and platelet aggregation
Skin of grapes, 
blueberries, 
raspberries, 
mulberries, peanuts, 
and red wine
Table 1. 
Mechanisms of iron regulation by antioxidants.
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that were exposed to either ethanol or excess iron and increase BMP6, intranuclear 
SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, lead-
ing to decreased hepatic iron levels and reduced iron-related damage [81]. Another 
potent antioxidant is genistein. It reduces inflammation induced by ethanol and 
oxidative stress in mice [82] and, similar to quercetin, increases HAMP promoter 
activity in both zebrafish and human hepatocytes via Stat3- and Smad4-dependent 
process [83]. Silymarin, another flavonoid, is present in milk thistle plant extract 
and may have iron-chelating properties [84]. It is safe, well tolerated, cost-effective 
alternative to currently available iron chelation therapies for treating patients 
with β-thalassemia [84]. Ferulic acid is present in a wide variety of plants, and the 
antioxidant effects are believed to be mediated via the neutralization of free radicals 
[85]. The antioxidant effects of resveratrol may prevent adverse changes that lead to 
cardiovascular disease by modulating vascular cell function, low density lipoprotein 
(LDL) oxidation, and platelet aggregation, thereby reducing myocardial damage 
[86, 87]. Both vitamin A and vitamin C have well-established antioxidant proper-
ties that are mediated via the attenuation of oxidative damage [88]. Vitamin A and 
β-carotene increase hepcidin and TfR expression and intestinal iron absorption, 
reduce inflammatory signaling and ferroportin expression, increase intracellular 
ferritin levels, and release intracellular trapped iron [89–91]. Vitamin C reduces 
Fe3+ to Fe2+ and inhibits hepcidin expression [92]. In recent years, research for new 
therapies based on plant-derived compounds has developed considerably. This is to 
maximize the benefits of plant phytochemicals and avoid the adverse effects often 
associated with synthetic pharmaceutical agents [93]. Several plant extracts, such 
as tucum-do-cerrado, astragalus, Angelica sinensis, Caulis Spatholobi, Scutellaria 
baicalensis, and others, have been studied for their putative effects on iron homeo-
stasis and oxidative stress. The results obtained are very promising (for esaustive 
review, see Ref. [76]).
Figure 3. 
Summary of the mechanisms regulating iron and oxidative stress by antioxidants. BMP6-SMAD-HAMP: 
Bone morphogenetic factor-mothers against decapentaplegic homolog-hepcidin antimicrobial peptide; GPx: 
Glutathione peroxidase;Nrf2-ARE: Nuclear factor erythroid 2-related factor 2-antioxidant response element; 
SOD: Superoxide dismutase.
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7. Conclusions
Alteration in iron homeostasis is associated with oxidative stress and inflamma-
tion. Many bioactive antioxidants and plant-derived phytochemicals can regulate 
iron homeostasis, inflammation, and oxidative stress. Nevertheless, the majority of 
data collected to date are derived from in vitro and animal experiments, and further 
studies are needed in order to evaluate the efficacy of these phytochemicals as a 
natural substitute for pharmaceutical agents. This is very important because many 
pharmaceutical agents are associated with adverse side effects.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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